{"title":"如何克服早期和转移性乳腺癌的内分泌抵抗","authors":"E. Biskup, M. Vetter","doi":"10.33582/2638-4248/1005","DOIUrl":null,"url":null,"abstract":"According to St. Gallen Consensus, endocrine responsive breast cancer is defined by positive steroidal receptors (ER= estrogen receptor and PR= Progesterone Receptor). ER/PR and HER2 are the most important biomarkers in decisionmaking about adjuvant and palliative treatment options. Available data suggest, that the higher the expression of ER and PR, the better the outcome for patients with early and advanced breast cancers.","PeriodicalId":433633,"journal":{"name":"Chronicles of Oncology","volume":"76 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"How to overcome endocrine resistance in early and metastatic breast cancer\",\"authors\":\"E. Biskup, M. Vetter\",\"doi\":\"10.33582/2638-4248/1005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"According to St. Gallen Consensus, endocrine responsive breast cancer is defined by positive steroidal receptors (ER= estrogen receptor and PR= Progesterone Receptor). ER/PR and HER2 are the most important biomarkers in decisionmaking about adjuvant and palliative treatment options. Available data suggest, that the higher the expression of ER and PR, the better the outcome for patients with early and advanced breast cancers.\",\"PeriodicalId\":433633,\"journal\":{\"name\":\"Chronicles of Oncology\",\"volume\":\"76 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-06-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chronicles of Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33582/2638-4248/1005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronicles of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33582/2638-4248/1005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
How to overcome endocrine resistance in early and metastatic breast cancer
According to St. Gallen Consensus, endocrine responsive breast cancer is defined by positive steroidal receptors (ER= estrogen receptor and PR= Progesterone Receptor). ER/PR and HER2 are the most important biomarkers in decisionmaking about adjuvant and palliative treatment options. Available data suggest, that the higher the expression of ER and PR, the better the outcome for patients with early and advanced breast cancers.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
